Aether Industries (AETHER) Q3 25/26 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 25/26 earnings summary
9 Jul, 2026Executive summary
Q3 FY26 revenue grew 44% year-over-year to INR 3,171 million, with EBITDA up 75% and PAT up 49%, driven by increased CEM contracts and LSM demand.
Strong performance across all business verticals, with export revenue at 36% and domestic at 64%.
Major capacity expansions at Site 3++ and Site 5 completed, with commercial production to commence by March 2026.
15 new customers onboarded and 36 customer/certification audits completed in 9M FY26.
Board approved unaudited standalone and consolidated financial results for Q3 and nine months ended December 31, 2025, reviewed by independent auditors.
Financial highlights
Q3 FY26 operating revenue: INR 3,171 million; EBITDA: INR 1,083 million; PAT: INR 645 million; EBITDA margin at 34%, up from 28% in Q3 FY25.
Nine-month FY26 revenue at INR 8,534 million, up 43% year-over-year; EBITDA up 75% to INR 2,716 million; PAT at INR 1,655 million, up 53%.
EPS (consolidated, Q3): INR 4.86; EPS (standalone, Q3): INR 3.92.
One-time FLOP insurance claim of INR 15 crore included in other income.
Paid-up equity share capital: INR 1,326.13 million.
Outlook and guidance
Targeting 70% of future revenue from CRAMS and CEM, 30% from large-scale manufacturing.
Sustainable EBITDA margin expected around 29-30% due to normalization after one-time items.
Site 3++ and Site 5 to reach 45-50% and 35-40% utilization respectively in FY27.
R&D expansion ongoing, with new fume hoods and a new R&D center under development.
Management is evaluating the impact of new labour codes and expects no material effect on results.
Latest events from Aether Industries
- Q1 FY27 delivered 27% revenue growth, margin expansion, and major R&D and insurance milestones.AETHER
Q1 26/2731 Jul 2026 - Q4 FY25 revenue up 90% Y/Y, PAT up 3621% Y/Y, with strong expansion and risk management.AETHER
Q4 24/259 Jul 2026 - Q3 FY25 delivered strong revenue and profit growth, supported by expansion and new contracts.AETHER
Q3 24/258 Jul 2026 - Q1 FY26 revenue up 35% Y/Y, EBITDA up 94%, with major expansions and Milliken contract signed.AETHER
Q1 25/268 Jul 2026 - 38% revenue growth and strong EBITDA, with R&D expansion and insurance claims ongoing.AETHER
Q4 25/2630 Jun 2026 - Q1 FY25 delivered strong growth, margin recovery, and major capital raise approval.AETHER
Q1 24/252 Feb 2026 - Q2 and H1 FY25 delivered strong growth, robust margins, and ongoing expansion initiatives.AETHER
Q2 24/2519 Dec 2025 - Q2 FY26 delivered 38% revenue and 70% EBITDA growth, with CEM/CRAMS over 50% of sales.AETHER
Q2 25/2619 Dec 2025